GHA Secures ￥50 Million in Series A Funding

(VCBeat) May. 8, 2021 -- Global Health Ark Medical Technology（Beijing）Co., Ltd. ("GHA") recently completed a Series A financing of over 50 million yuan, with participation from China Venture Capital, Fortune Venture Capital and Tasly Capital. Nesthill Capital served as the exclusive financial adviser.

As the first non-invasive glucose meter developer obtaining the first non-invasive glucose meter certification in China, GHA will use the funds for the production and promotion of the family-version non-invasive glucose meter, and the certification and production of the portable version of the non-invasive glucose meter, which will lay a foundation for the company's future development and subsequent financing.

GHA is a high-tech company that combines university research and industrial production, focusing on the development of innovative medical devices. To follow the principle of "understanding the consumer and promoting innovation" and to achieve medical digitization, GHA collaborates with the Department of Precision Instrument of Tsinghua University and other academies to provide new early-stage screening and management solutions for chronic diseases through product innovations that are driven by clinical demands.

Compared with the traditional blood glucose meter by fingertip sampling, the non-invasive glucose meter developed and produced by GHA will greatly improve patient compliance, popularize blood glucose detection, promote the efficiency of blood glucose management, reduce the harm of diabetes and improve the health of people. In 2020, GHA's second generation (family-version) non-invasive glucose meter was approved for the third-class medical device registration certificate. In addition, its third generation (personal-version) non-invasive glucose meter is expected to be approved in the near future.

Established in 2000, China Venture Capital is a professional investor with venture capital and fund management as its main businesses. It is one of the important pioneers in the local venture capital market in China.

The company currently manages dozens of RMB funds. The company's investment covers angel rounds, venture capital, equity funds, industrial merger and acquisition, etc. The company's key investment areas include energy conservation and environmental protection, new materials, new energy, high-end manufacturing, rail transit, military aerospace, medicine and healthcare, Internet, etc.

Founded in April 2000, Fortune Capital is one of the earliest market-oriented venture capital firms in China. For the past 14 years, Fortune Capital focuses its investments on leading companies in four key sectors: TMT (Media oriented), Consumer Goods/Services, Modern Agriculture and Clean Tech.

Fortune Capital is ranked among the highest performing VC/PE firms in China. In addition to providing capital, Fortune Capital provides its investee companies with personalized value-added services.